Compass Therapeutics (CMPX) Gains from Sales and Divestitures (2020 - 2026)
Compass Therapeutics recorded quarterly Gains from Sales and Divestitures of $284000.0 in Q1 2026, down 73.53% quarter-over-quarter from $1.1 million in Q4 2025, and down 65.49% year-over-year from $823000.0 in Q1 2025.
Compass Therapeutics' Gains from Sales and Divestitures history runs 7 years deep, the most recent figure standing at $284000.0 for Q1 2026.
- In Q1 2026, Gains from Sales and Divestitures fell 65.49% year-over-year to $284000.0; the TTM figure through Mar 2026 stood at $284000.0 (down 65.49% YoY), while the FY2025 annual figure was $1.1 million, up 104.38% from the prior year.
- Gains from Sales and Divestitures came in at $284000.0 for Q1 2026 at Compass Therapeutics, down from $1.1 million in the prior quarter.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $1.1 million in Q4 2025 to a low of $73000.0 in Q1 2022.
- A 5-year average of $474916.7 and a median of $300000.0 in 2022 frame the typical range for Gains from Sales and Divestitures.
- Across the five-year window, Gains from Sales and Divestitures surged 265.78% in 2025 and tumbled 65.49% in 2026, its largest moves.
- Compass Therapeutics' Gains from Sales and Divestitures stood at $300000.0 in 2022, then changed by 0.0% to $300000.0 in 2023, then soared by 75.0% to $525000.0 in 2024, then jumped by 104.38% to $1.1 million in 2025, then sank by 73.53% to $284000.0 in 2026.
- According to Business Quant data, Gains from Sales and Divestitures over the past three periods registered $284000.0, $1.1 million, and $823000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Compass Therapeutics | 418.47 Mn | 223.78 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 284,000.00 |
| Mar 31, 2026 | 284,000.00 |
| Dec 31, 2025 | 1.07 Mn |
| Dec 31, 2025 | 1.07 Mn |
| Sep 30, 2025 | 823,000.00 |
| Sep 30, 2025 | 823,000.00 |
| Jun 30, 2025 | 823,000.00 |
| Jun 30, 2025 | 823,000.00 |
| Mar 31, 2025 | 823,000.00 |
| Mar 31, 2025 | 823,000.00 |
| Dec 31, 2024 | 525,000.00 |
| Dec 31, 2024 | 525,000.00 |
| Sep 30, 2024 | 225,000.00 |
| Sep 30, 2024 | 225,000.00 |
| Jun 30, 2024 | 225,000.00 |
| Jun 30, 2024 | 225,000.00 |
| Mar 31, 2024 | 225,000.00 |
| Mar 31, 2024 | 225,000.00 |
| Dec 31, 2023 | 300,000.00 |
| Dec 31, 2023 | 300,000.00 |
| Dec 31, 2022 | 300,000.00 |
| Dec 31, 2022 | 300,000.00 |
| Mar 31, 2022 | 73,000.00 |
| Mar 31, 2022 | 73,000.00 |
| Sep 30, 2021 | 273,000.00 |
| Sep 30, 2021 | 273,000.00 |
| Mar 31, 2021 | 93,000.00 |
| Mar 31, 2021 | 93,000.00 |
| Dec 31, 2020 | 474,000.00 |
| Dec 31, 2020 | 474,000.00 |
| Sep 30, 2020 | 277,815.00 |
| Sep 30, 2020 | 277,815.00 |
| Jun 30, 2020 | 150,379.00 |
| Jun 30, 2020 | 150,379.00 |